Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine i...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamini, Ohad, Rokach, Lior, Itchaki, Gilad, Braester, Andrei, Shvidel, Lev, Goldschmidt, Neta, Shapira, Shirley, Dally, Najib, Avigdor, Abraham, Rahav, Galia, Lustig, Yaniv, Ben David, Shirley Shapiro, Fineman, Riva, Paz, Alona, Bairey, Osnat, Polliack, Aaron, Levy, Ilana, Tadmor, Tamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883569/
https://www.ncbi.nlm.nih.gov/pubmed/34320789
http://dx.doi.org/10.3324/haematol.2021.279196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883569/
https://www.ncbi.nlm.nih.gov/pubmed/34320789
http://dx.doi.org/10.3324/haematol.2021.279196

Ejemplares similares